Refine by
T Cell Technology
35 companies found
Technologybased inMünchen, GERMANY
We are an interdisciplinary team with a focus on research, translation, clinical development, manufacturing, and commercialization. Our passionate team is committed to provide safe and effective tumor therapy. We are supported by a strong scientific ...
The FUSIX Technology relies on a fusion-based oncolytic virus platform. Below you can see FUB101 in action. In this timelapse video FUB101 is killing a monolayer of cancer cells (HCC) within 48 hours through a fusogenic mechanism of action. ...
Technologybased inAustin, TEXAS (USA)
Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more ...
Covered by Medicare, Prospera is a transplant rejection assessment test that uses a simple blood draw to evaluate the risk of rejection of a transplanted kidney. Through the use of advanced cell-free DNA technology, Prospera increases a ...
Technologybased inSALUGGIA, ITALY
We are global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments. For over 50 years we have been dealing with diagnostics to help physicians and patients make better decisions in the ...
Thanks to its team of dedicated scientists, DiaSorin has developed a new concept assay to maximize EARLY Lyme borreliosis detection through a unique combination of humoral and cell mediated immunity. The unique diagnostic value of B ...
Technologybased inSan Carlos, CALIFORNIA (USA)
CellFE is a venture-backed company with a mission to make advanced therapies accessible to all by transforming the way gene therapies are manufactured. The company uses a microfluidics-based cell engineering platform that can be adapted universally ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
Emerging from the Company’s proprietary ATAK™ CAR receptor library, Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this ...
Technologybased inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
The Celluris’ novel solution, named RfuCAR, was engineering in order to respond some challenges addressed by clinical trials around the world. RfuCAR is a bispecific in tandem receptor CAR, that is composed by an antigen binding domain and ...
Technologybased inViken, SWEDEN
TIKOMED AB is a privately owned company based in Viken, Sweden. It is governed by the Laws of the Kingdom of Sweden and was formed in accordance with the Swedish Company Act in 2002. We develop and commercialize innovative treatments for patients ...
Cell therapies are associated with graft loss. It involves activation of the complement and coagulation cascades when cells come into contact with blood, ultimately resulting in cell death. IBSOLVMIR is an infusion product that inhibits IBMIR and ...
Technologybased inSeoul, SOUTH KOREA
GI Innovation is a bio-venture company that researches and develops innovative protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and ...
Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the ...
Technologybased inColumbia, MARYLAND (USA)
Hemagen Inc. was founded in 1985 by a group of scientists from the Boston University School of Medicine. Hemagen's mission is to offer high quality diagnostic test kits in user friendly formats. We continue to the highest quality gold standard test ...
Technologybased inMawson Lakes, AUSTRALIA
Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. CAR-T therapy is a revolutionary new treatment option that uses a ...
Advanced colorectal cancer currently has a poor prognosis and is the deadliest form of cancer for Australians 25 to 34 years old. LGR5 is a cancer stem cell marker that is highly expressed on advanced colorectal cancer and other cancers. In colon ...
Technologybased inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
We believe VCAR33 could be a potent anticancer therapy that, when combined with VOR33, could help obviate severe on-target myeloablative toxicities and unlock the efficacy potential of VCAR33. In addition, in this setting, VCAR33 T ...
Technologybased inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
AdAlta and Carina Biotech to develop next-generation i-body enabled CAR-T cancer therapeutics. AdAlta has entered a collaboration agreement with Carina Biotech to develop next-generation i-body enabled CAR-T ...
Technologybased inWien, AUSTRIA
BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and ...
The high level of interferon induced by the delNS vector activates immunological defence reactions against cancer. It also stimulates the production of antiviral ...
Technologybased inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated ...
Technologybased inHayward, CALIFORNIA (USA)
We are a biotech startup in the San Francisco Bay Area founded in February 2017. We focus on developing complex antibodies with enhanced efficacy, safety, and manufacturability features against difficult-to-treat diseases including cancer, ...
Humanization percentage, CDR Immunogenicity, Antigen binding affinity, Antibody expression level, Aggregation potential, Antibody stability, ...
Technologybased inHørsholm, DENMARK
We are an AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases. We have developed our AI-immunology core technology to deeply understand the biological ...
RAVEN combines the essential AI tools from our PIONEER platform with structural bioinformatic tools from EDEN to arrive at a novel potent T- and B-cell vaccine design for emerging and mutating viral ...
Technologybased inRixensart, BELGIUM
CuraVac is a clinical-stage biotech company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines for the treatment of autoimmune diseases. The company was founded by a ...
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
Technologybased inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
A combination therapy consisting of PKC agonists with or without HDAC inhibitors, designed to reactivate latent HIV reservoirs so that HIV can be eliminated by antiviral therapy and eradicated from the body. HIV Latency: Although highly active ...
Technologybased inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Technologybased inOxford, UNITED KINGDOM
Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer. The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford ...
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been ...
